by I. Edwards
Moderna’s new flu vaccine, primarily based on the identical mRNA know-how utilized in its COVID-19 shot, confirmed promising leads to a serious trial, the corporate introduced Monday.
The vaccine, referred to as mRNA-1010, was examined in a Phase 3 study in adults aged 50 and older. It labored higher than a standard-dose flu vaccine, offering 26.6% extra safety towards the flu general, the corporate stated.
In adults 65 and older, the vaccine confirmed a 27.4% enchancment.
“The severity of this past flu season underscores the necessity for simpler vaccines,” Moderna CEO Stéphane Bancel advised The Wall Street Journal.
“An mRNA-based flu vaccine has the potential benefit to extra exactly match circulating strains, assist fast response in a future influenza pandemic, and pave the way in which for COVID-19 mixture vaccines,” he added.
Moderna stated the trial confirmed sturdy leads to people throughout totally different age teams, well being situations and even amongst individuals who had been vaccinated for the flu up to now.
The firm plans to current the total knowledge at an upcoming medical convention and publish the leads to a peer-reviewed journal.
Moderna additionally stated it’ll work with well being regulators on the subsequent steps for doable approval of the vaccine, The Wall Street Journal stated.
The information comes amid persevering with curiosity in mRNA vaccine know-how, at the same time as public views shift. Moderna gained prominence through the COVID-19 pandemic however now faces extra political scrutiny because the Trump administration considers new guidelines for vaccines.
The new outcomes helped enhance Moderna’s inventory by greater than 4% in early buying and selling Monday, although the corporate’s shares are nonetheless down about 32% for the yr.
More data:
Moderna has extra on the science behind mRNA.
Citation:
Moderna’s new flu shot exhibits sturdy leads to older adults ( 1)
3
moderna-flu-shot-strong-results.html
.
. The content material is supplied for data functions solely.